Peter Jones, Ph.D., D.Sc. (hon)

Distinguished Professor

Department of Epigenetics

Van Andel Institute

Talk title: Targeting TET2 and Intercepting Myeloid Cancers with Vitamin C

Abstract: Mutations in genes which apply and remove DNA cytosine methylation, such as DNMT3A and TET2 are common in myeloid malignancies and precursor conditions such as clonal cytopenia of undetermined significance (CCUS). Cytosine methylation, in addition to having created CpG islands over evolution, plays a substantial role in the reversible control of enhancers, catalyzed by DNMT3A and TET2 respectively. Vitamin C is essential for TET2 activity, and our phase 2 randomized clinical trial shows that oral vitamin C may prolong the overall survival of CCUS patients with wild type, but not mutated TET2.

Host: Dr. Tim Schedl